How Shifting Vascular Cells Drive Coronary Artery Disease Risk

A new study published in Nature Communications has uncovered how changes in vascular smooth muscle cells (VSMCs) influence the risk of coronary artery disease (CAD). These cells, found in arterial walls, can shift between different states—some of which worsen plaque buildup and inflammation. The findings suggest fresh avenues for treating a condition affecting millions worldwide.

The research, combining computational modelling and genetic data, maps how VSMC transitions contribute to disease progression. Scientists believe these insights could reshape cardiovascular treatment strategies.

VSMCs were once seen as static components of blood vessels, but the study confirms their dynamic nature. They can adopt multiple states, from contractile (maintaining vessel function) to synthetic (promoting tissue repair or plaque formation). When these transitions go wrong, they accelerate vascular inflammation and weaken plaques, raising CAD risk.

The team used single-cell analytics to track VSMC state changes during disease. They identified key transitional phases linked to higher susceptibility to arterial blockages. Genetic analysis then revealed overlaps between these transitions and known CAD risk factors—certain gene variants appear to disrupt regulatory pathways controlling VSMC behaviour.

Two major signalling systems—TGF-β and Notch—were pinpointed as regulators of VSMC plasticity. Transcription factors like KLF4 and myocardin act as molecular switches, tipping the balance between healthy and harmful cell states. Epigenetic changes further lock in detrimental phenotypes, making reversal more difficult.

In vivo experiments validated the single-cell findings. Mice with manipulated VSMC states developed lesions matching human CAD patterns, confirming the role of these transitions in disease severity. However, translating these results into human therapies remains challenging. Preclinical tests show potential for reversing maladaptive plasticity, but risks include unintended effects on other vascular cells and restenosis (re-narrowing of arteries).

The study also challenges long-held assumptions about vascular lesions. Rather than passive damage, the data suggest VSMC plasticity actively drives lesion formation. This shift in understanding could refocus research on targeting cell state transitions rather than just cholesterol or inflammation.

The findings offer a detailed roadmap of VSMC behaviour in CAD, with implications for 20–30 million global patients. Therapies targeting KLF4 or related pathways could theoretically stabilise plaques and reduce inflammation. Yet hurdles remain, including precise drug delivery and avoiding side effects in healthy vessels.

By integrating single-cell data, genetics, and live validation, the work sets a benchmark for future cardiovascular research. Clinical applications may still be years away, but the study provides a clearer picture of how vascular cells contribute to heart disease.